Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Zosano Pharma Corporation ZSAN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
35/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Zosano Pharma Corporation (ZSAN) is a Biotechnology company in the Healthcare sector, currently trading at $0.56. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 2 out of 7 criteria passed.

Financials: revenue is $785,000, +250.4%/yr average growth. Net income is $30M (loss), growing at +4.9%/yr. Net profit margin is -3836.2% (negative). Gross margin is -1.4% (-25.1 pp trend).

Balance sheet: total debt is $9M against $33M equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 1.04 (adequate). Debt-to-assets is 19.6%. Total assets: $48M.

Analyst outlook: 6 / 8 analysts rate ZSAN as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 73/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 75/100 (Pass), Income 10/100 (Fail).

ZSAN SharesGrow Score Overview

52/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 75/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ZSAN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
73/100
ZSAN: +250.4%/yr revenue is, +4.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ZSAN: Debt-to-Equity (D/E) ratio 0.29 (conservative), Current ratio is 1.04 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
✓
FUTURE Pass
75/100
Analyst outlook: 6 / 8 analysts rate ZSAN as buy (75%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ZSAN: Net profit margin is -3836.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.46-0.635
Volume1.16M
Avg Volume (30D)5.36M
Beta (1Y)3.29
Share Statistics
EPS (TTM)-0.27
Shares Outstanding$112.06M
IPO Date2015-01-27
Employees40
CEOSteven Lo
Financial Highlights & Ratios
Revenue (TTM)$785K
Gross Profit$-11K
EBITDA$-27.99M
Net Income$-30.11M
Operating Income$-29.74M
Total Cash$11.04M
Total Debt$9.48M
Net Debt$-1.56M
Total Assets$48.39M
Price / Earnings (P/E)-2.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering8
Buy 75% Hold 25% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS98979H3012

Price Chart

Track all markets on TradingView
ZSAN
Zosano Pharma Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.46 52WK RANGE 0.64

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message